Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T20710
(Former ID: TTDS00139)
|
|||||
| Target Name |
Interleukin 2 receptor (IL2R)
|
|||||
| Synonyms |
p64; gammaC; Interleukin2 receptor subunit gamma; Interleukin-2 receptor subunit gamma; IL2R subunit gamma; IL2 receptor subunit gamma; IL-2RG; IL-2R subunit gamma; IL-2R; IL-2 receptor subunit gamma; Cytokine receptor common subunit gamma; CD132
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Leukaemia [ICD-11: 2A60-2B33] | |||||
| Function |
Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. Common subunit for the receptors for a variety of interleukins.
Click to Show/Hide
|
|||||
| BioChemical Class |
Cytokine receptor
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Denileukin diftitox | Drug Info | Approved | leukaemia | [2], [3] | |
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | ALKS 4230 | Drug Info | Phase 2 | Solid tumour/cancer | [4] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Binder | [+] 1 Binder drugs | + | ||||
| 1 | Denileukin diftitox | Drug Info | [1] | |||
| Agonist | [+] 1 Agonist drugs | + | ||||
| 1 | ALKS 4230 | Drug Info | [5] | |||
| Antagonist | [+] 1 Antagonist drugs | + | ||||
| 1 | Ro26-4550 | Drug Info | [6] | |||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| KEGG Pathway | [+] 7 KEGG Pathways | + | ||||
| 1 | Cytokine-cytokine receptor interaction | |||||
| 2 | Endocytosis | |||||
| 3 | PI3K-Akt signaling pathway | |||||
| 4 | Jak-STAT signaling pathway | |||||
| 5 | Hematopoietic cell lineage | |||||
| 6 | Measles | |||||
| 7 | HTLV-I infection | |||||
| Reactome | [+] 6 Reactome Pathways | + | ||||
| 1 | GPVI-mediated activation cascade | |||||
| 2 | Interleukin-7 signaling | |||||
| 3 | G beta:gamma signalling through PI3Kgamma | |||||
| 4 | Interleukin-2 signaling | |||||
| 5 | RAF/MAP kinase cascade | |||||
| 6 | Interleukin receptor SHC signaling | |||||
| WikiPathways | [+] 7 WikiPathways | + | ||||
| 1 | IL-2 Signaling Pathway | |||||
| 2 | Inflammatory Response Pathway | |||||
| 3 | Interleukin-2 signaling | |||||
| 4 | Allograft Rejection | |||||
| 5 | TSLP Signaling Pathway | |||||
| 6 | IL-7 Signaling Pathway | |||||
| 7 | Interleukin-3, 5 and GM-CSF signaling | |||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. | |||||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7044). | |||||
| REF 3 | Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs. 2008 Jun;13(2):345-61. | |||||
| REF 4 | ClinicalTrials.gov (NCT04592653) A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment (ARTISTRY-3). U.S. National Institutes of Health. | |||||
| REF 5 | ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673. | |||||
| REF 6 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2297). | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.